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Introduction
Bupivacaine toxicity is a recognized compli-
cation of procedures done under local anes-
thetic infiltration. While local anesthetic toxi-
city is rare, it is potentially catastrophic and
life-threatening.
1 A  20%  lipid  emulsion  has
been used to resuscitate patients after bupiva-
caine  overdose  or  inadvertent  intravascular
injection.
2-7 While the use of lipid emulsion for
local  anesthetic  toxicity  has  been  reported
extensively in the anesthesia literature,
8it has
not yet been reported in the cardiology litera-
ture. We report a case of local anesthetic toxi-
city  resulting  in  pulseless  electrical  activity
during  an  electrophysiology  procedure  that
was successfully treated by infusion of 20%
lipid emulsion.  
Case Report 
A 28-year old male from El Salvador (1.58 m,
55.8 kg) with no significant past medical his-
tory presented to a community hospital with a
3-month  history  of  worsening  shortness  of
breath, dyspnea on exertion, fatigue, nausea
and vomiting. The patient denied chest pain,
fevers, chills, recent febrile illness, sick con-
tacts or palpitations. 
The patient was found to be in sinus rhythm
with  complete  heart  block  (3rd  degree  AV
block) and a junctional escape rhythm of 30
bpm. He was then transferred to our institu-
tion where he underwent emergent placement
of a right internal jugular transvenous pacing
wire for temporary pacing. Further evaluation
showed the patient to have a nonischemic car-
diomyopathy with an echocardiogram demon-
strating a left ventricular ejection fraction of
12% with severe global hypokinesis. 
The patient was scheduled for a biventricu-
lar  implantable  cardioverter  defibrillator
(ICD) implant. In the electrophysiology suite,
the patient had standard monitors placed and
oxygen was delivered at 3 L/min via nasal can-
nula. Intravenous cefazolin 1 g was given as
prophylaxis, with fentanyl 12.5 mg and midazo-
lam 2 mg administered intravenously. During
this period the patient was comfortable, awake
and able to communicate.  
During the procedure, the patient received
a total of 50 cc of local anesthetic injection
comprised of a mixture of 2% lidocaine and
0.5%  bupivacaine  to  the  left  subpectoral
region to facilitate left axillary venous access
and construction of a subpectoral pocket for
the device. The heart rate and blood pressure
remained stable during injection of local anes-
thetic.  Soon  after  obtaining  axillary  venous
access,  the  patient  complained  of  dizziness
but with no changes in blood pressure, heart
rate or pulse oximetry. Several minutes later
he exhibited generalized seizure activity with
severe tonic-clonic activity. Initially, midazo-
lam 1 mg IV and then lorazepam 2 mg IV was
used  to  treat  the  seizure  while  a  bag  valve
mask  was  used  to  support  ventilation.  The
patient remained hemodynamically stable dur-
ing this episode. Urgent anesthesiology con-
sultation was requested and the patient was
intubated without complication. Subsequently,
the patient was noted to have pulseless electri-
cal activity and cardiopulmonary resuscitation
was immediately started. Advanced cardiac life
support  protocol  was  initiated  during  which
the patient received a total of 4 mg epineph-
rine, 40 U of vasopressin, 4 mg atropine, nor-
mal saline bolus and 200 meq sodium bicar-
bonate. An echocardiogram demonstrated no
pericardial effusion. Bupivacaine toxicity was
suspected as the cause for the cardiac arrest
and the patient was given 2 units of 20% lipid
emulsion. During the second dose of 20% lipid
emulsion  infusion,  the  patient  regained  his
pulse  and  became  hemodynamically  stable.
The  pocket  was  closed  after  rinsing  with
antibiotics. A CT scan of the brain and a neu-
rology consultation were unrevealing. Several
hours after intubation and cardiac arrest the
patient was successfully extubated. 
Approximately one week later, the patient
had  successful  placement  of  a  biventricular
ICD without complication. No bupivacaine was
used. Several days later the patient was dis-
charged home.  
Discussion
The  anesthesiology  community  has  had
extensive experience with local anesthetics as
well as their complications.
1,8,9 As a result, the
use of lipid emulsion to rescue patients with
local anesthetic toxicity is well known to anes-
thesiologists  but  perhaps  less  to  cardiolo-
gists.
2,3,5 The  proposed  mechanism  of  intra  -
lipids action is the “lipid sink” binding. In this
proposed  mechanism,  the  lipids  “bind”  the
lipophilic bupivacaine and reduce tissue con-
tent. The first reported use of lipid therapy in
patients was in 2006, with the successful res-
cue  of  patients  undergoing  regional  blocks
who  failed  to  respond  to  conventional  car-
diopulmonary  resuscitation  after  showing
signs of local anesthetic toxicity. The patients
were successfully resuscitated after treatment
with lipid emulsion.
10,11 Weinberg et al. demon-
strated that intravenous lipid emulsion thera-
py  increases  resistance  to,  and  enhances
resuscitation of, rats and dogs exposed to local
anesthetic  overdoses.
12-14 Importantly,  while
lipids have been shown to be helpful in treat-
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ing lipophilic local anesthetics such as bupiva-
caine,  levobupivicaine,  ropivicaine,  and
mepivicaine, they do not treat toxicity from the
more  hydrophilic  local  anesthetics  such  as
lidocaine.
While no serum levels were drawn during
the resuscitation in this case, we are confident
the events were secondary to local anesthetic
toxicity due to the timing, the clinical presen-
tation consistent with local anesthetic toxicity
(dizziness, hypotension, seizure activity, and
arrhythmia)
8 and the immediate resuscitation
following  administration  of  20%  lipid  emul-
sion. It is well documented that bupivacaine
toxicity first manifests as central nervous sys-
tem disorders (tinnitus, a metallic taste in the
mouth,  dizziness,  seizures).  Cardiovascular
signs follow the neurologic signs and include
bradycardia,  dysrhythmias  and,  in  severe
cases, asystole.
8
This patient received 50 cc of a combination
of 2% lidocaine and 0.5% bupivacaine (in a 4:3
ratio) yielding a total dose of 570 mg of lido-
caine and 107 mg of bupivicaine. In this size
patient, that yields a dose of 10 mg/kg of lido-
caine plus 1.9 mg/kg of bupavicaine. The max-
imum local anesthetic dose for lidocaine is 4.5
mg/kg and the maximum dose for bupivacaine
is 2.5 mg/kg. Therefore, this patient received a
toxic dose of lidocaine plus a dose of bupiva-
caine approaching the upper limit. 
In summary, this case represents the first
reported case of local anesthetic cardiotoxicity
with successful reversal using lipid emulsion
in the electrophysiology laboratory, a site that
frequently  utilizes  local  anesthetics.  Bup  -
ivacaine toxicity and the use of lipid emulsion
as rescue therapy should be considered in all
cases in which symptoms consistent with local
anesthetic toxicity occur. Furthermore, all clin-
ical sites where local anesthetics are routinely
used should have 20% lipid emulsion readily
available  and  personnel  should  be  educated
regarding this medication. Published evidence
to date suggests that lipid rescue for presumed
local anesthetic toxicity should be considered
in  prolonged  cardiopulmonary  resuscitation
when there is suspicion of local anesthetic tox-
icity.  
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